{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "c267ba31-72f9-4bd2-a947-16c753db6933",
   "metadata": {},
   "outputs": [],
   "source": [
    "{\n",
    "   \"instruction\":\"The following are multiple choice questions (with answers) about medical knowledge.\",\n",
    "   \"shots\":[\n",
    "      {\n",
    "         \"question\": \"A 32-year-old woman with bipolar disorder visits her gynecologist because she believes she is pregnant. A urine pregnancy test is performed which confirms she is pregnant. She has mild bipolar disorder for which she takes lithium and admits that she has been taking it ‘on and off’ for 2 years now but has never had any symptoms or episodes of relapse. She says that she had not made contact with her psychiatrist for the past several months because she ‘couldn’t find any time.’ Which of the following is the next best step in the management of this patient?\",\n",
    "         \"choices\": [\n",
    "            \"Taper lithium and administer valproate\",\n",
    "            \"Continue lithium administration through pregnancy and add lamotrigine\",\n",
    "            \"Taper lithium and administer carbamazepine\",\n",
    "            \"Taper lithium and provide a prescription for clonazepam as needed\"\n",
    "         ],\n",
    "         \"answer\": \"D\",\n",
    "         \"answer_text\": \"Taper lithium and provide a prescription for clonazepam as needed\"\n",
    "      },\n",
    "      {\n",
    "         \"question\": \"A 22-year-old man is brought to the emergency department 10 minutes after falling down a flight of stairs. An x-ray of the right wrist shows a distal radius fracture. A rapidly acting intravenous anesthetic agent is administered, and closed reduction of the fracture is performed. Following the procedure, the patient reports palpitations and says that he experienced an “extremely vivid dream,” in which he felt disconnected from himself and his surroundings while under anesthesia. His pulse is 110/min and blood pressure is 140/90 mm Hg. The patient was most likely administered a drug that predominantly blocks the effects of which of the following neurotransmitters?\",\n",
    "         \"choices\": [\n",
    "            \"Glutamate\",\n",
    "            \"Norepinephrine\",\n",
    "            \"Endorphin\",\n",
    "            \"Gamma-aminobutyric acid\"\n",
    "         ],\n",
    "         \"answer\": \"A\",\n",
    "         \"answer_text\": \"Glutamate\"\n",
    "      },\n",
    "      {\n",
    "         \"question\": \"A 65-year-old man comes to the physician because of increasing swelling of the legs and face over the past 2 months. He has a history of diastolic heart dysfunction. The liver and spleen are palpable 4 cm below the costal margin. On physical examination, both lower limbs show significant pitting edema extending above the knees and to the pelvic area. Laboratory studies show significant findings. Which of the following best explains these findings?\",\n",
    "         \"choices\": [\n",
    "            \"AL amyloidosis\",\n",
    "            \"Smoldering multiple myeloma\",\n",
    "            \"Symptomatic multiple myeloma\",\n",
    "            \"Waldenstrom’s macroglobulinemia\"\n",
    "         ],\n",
    "         \"answer\": \"A\",\n",
    "         \"answer_text\": \"AL amyloidosis\"\n",
    "      },\n",
    "      {\n",
    "         \"question\": \"Background: Aldosterone blockade reduces mortality and morbidity among patients with severe heart failure. A study evaluating the effect of eplerenone, a selective aldosterone blocker, on morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure was conducted. Which of the following statements represents the most accurate interpretation of the results from the aforementioned clinical trial?\",\n",
    "         \"choices\": [\n",
    "            \"There was no significant difference in the incidence of hyperkalemia between trial arms.\",\n",
    "            \"There was no significant difference in the rate of sudden cardiac death between trial arms.\",\n",
    "            \"Eplerenone, when added to optimal medical therapy, decreases all cause mortality in patients with left ventricular dysfunction following myocardial infarction.\",\n",
    "            \"The most common causes of death seen in enrolled patients over the course of this trial were non-cardiac in nature.\"\n",
    "         ],\n",
    "         \"answer\": \"C\",\n",
    "         \"answer_text\": \"Eplerenone, when added to optimal medical therapy, decreases all cause mortality in patients with left ventricular dysfunction following myocardial infarction.\"\n",
    "      },\n",
    "      {\n",
    "         \"question\": \"A 2-day-old newborn boy has failed to pass meconium after 48 hours. There is an absence of stool in the rectal vault. Family history is significant for MEN2A syndrome. Which of the following confirms the diagnosis?\",\n",
    "         \"choices\": [\n",
    "            \"Absence of ganglion cells demonstrated by rectal suction biopsy\",\n",
    "            \"Atrophic nerve fibers and decreased acetylcholinesterase activity\",\n",
    "            \"Barium enema demonstrating absence of a transition zone\",\n",
    "            \"Rectal manometry demonstrating relaxation of the internal anal sphincter with distension of the rectum\"\n",
    "         ],\n",
    "         \"answer\": \"A\",\n",
    "         \"answer_text\": \"Absence of ganglion cells demonstrated by rectal suction biopsy\"\n",
    "      }\n",
    "   ]\n",
    "}\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 67,
   "id": "d3e69ad0-71ee-413c-a162-dc0245d32a0e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'template_name': 'from_string',\n",
       " 'template_dir': None,\n",
       " 'environment': <jinja2.environment.Environment at 0x1051d8f40>,\n",
       " 'template': <Template memory:10528c0d0>}"
      ]
     },
     "execution_count": 67,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "template_st = \"\"\"{% if description %}{{ description }}\n",
    "{% endif %}{% if instruction %}{{ instruction }}\n",
    "{% else %}The following are multiple choice questions about medical research. Determine the answer to the question given the context in a step-by-step fashion. Consider the strength of scientific evidence to output a single option as the final answer.\n",
    "{% endif %}{% if examples %}{% for item in examples %}\n",
    "Context: {{ item.context }}\n",
    "Question: {{ item.question }}\n",
    "Choices:{% for choice in item.choices %} \n",
    "{{ loop.index0 | to_letter }}. {{ choice }}{% endfor %}{% for key, value in item.items() %}{% if key not in ['question', 'choices', 'answer', 'context', 'answer_text'] %}\n",
    "{{ key|capitalize }}: {{ value }}{% endif %}{% endfor %}\n",
    "Answer: {{ item.answer }}\n",
    "{% endfor %}{% endif %}\n",
    "\n",
    "Question: {{ question }}\n",
    "Choices:{% for choice in choices %}\n",
    "{{ loop.index0 | to_letter }}. {{ choice }}{% endfor %}\n",
    "Explanation: \n",
    "Answer: {{ answer }}\n",
    "\"\"\"\n",
    "\n",
    "tl = TemplateLoader().load_template(template_st, from_string = True)\n",
    "tl"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 68,
   "id": "d8af15a7-7e9b-4fd5-aaea-a7bc8de778a7",
   "metadata": {},
   "outputs": [],
   "source": [
    "sample =     {\n",
    "    \"question\": \"Are interstitial fluid concentrations of meropenem equivalent to plasma concentrations in critically ill patients receiving continuous renal replacement therapy?\",\n",
    "    \"context\" : \"To describe the interstitial fluid (ISF) and plasma pharmacokinetics of meropenem in patients on continuous venovenous haemodiafiltration (CVVHDF). This was a prospective observational pharmacokinetic study. Meropenem (500 mg) was administered every 8 h. CVVHDF was targeted as a 2-3 L/h exchange using a polyacrylonitrile filter with a surface area of 1.05 m2 and a blood flow rate of 200 mL/min. Serial blood (pre- and post-filter), filtrate/dialysate and ISF concentrations were measured on 2 days of treatment (Profiles A and B). Subcutaneous tissue ISF concentrations were determined using microdialysis. A total of 384 samples were collected. During Profile A, the comparative median (IQR) ISF and plasma peak concentrations were 13.6 (12.0-16.8) and 40.7 (36.6-45.6) mg/L and the trough concentrations were 2.6 (2.4-3.4) and 4.9 (3.5-5.0) mg/L, respectively. During Profile B, the ISF trough concentrations increased by ∼40%. Meropenem ISF penetration was estimated at 63% (60%-69%) and 69% (65%-74%) for Profiles A and B, respectively, using comparative plasma and ISF AUCs. For Profile A, the plasma elimination t1/2 was 3.7 (3.3-4.0) h, the volume of distribution was 0.35 (0.25-0.46) L/kg, the total clearance was 4.1 (4.1-4.8) L/h and the CVVHDF clearance was 2.9 (2.7-3.1) L/h.\",\n",
    "    \"choices\": [\n",
    "      \"Yes\",\n",
    "      \"No\",\n",
    "      \"Maybe\"\n",
    "    ],\n",
    "\n",
    "    \"explanation\": \"This is the first known report of concurrent plasma and ISF concentrations of a meropenem antibiotic during CVVHDF. We observed that the ISF concentrations of meropenem were significantly lower than the plasma concentrations, although the present dose was appropriate for infections caused by intermediately susceptible pathogens (MIC<=4 mg/L).\",\n",
    "    \"answer\": \"B\",\n",
    "    \"answer_text\": \"No\"\n",
    "  }\n",
    "\n",
    "\n",
    "examples = [\n",
    "  {\n",
    "    \"question\": \"Are interstitial fluid concentrations of meropenem equivalent to plasma concentrations in critically ill patients receiving continuous renal replacement therapy?\",\n",
    "    \"context\" : \"To describe the interstitial fluid (ISF) and plasma pharmacokinetics of meropenem in patients on continuous venovenous haemodiafiltration (CVVHDF). This was a prospective observational pharmacokinetic study. Meropenem (500 mg) was administered every 8 h. CVVHDF was targeted as a 2-3 L/h exchange using a polyacrylonitrile filter with a surface area of 1.05 m2 and a blood flow rate of 200 mL/min. Serial blood (pre- and post-filter), filtrate/dialysate and ISF concentrations were measured on 2 days of treatment (Profiles A and B). Subcutaneous tissue ISF concentrations were determined using microdialysis. A total of 384 samples were collected. During Profile A, the comparative median (IQR) ISF and plasma peak concentrations were 13.6 (12.0-16.8) and 40.7 (36.6-45.6) mg/L and the trough concentrations were 2.6 (2.4-3.4) and 4.9 (3.5-5.0) mg/L, respectively. During Profile B, the ISF trough concentrations increased by ∼40%. Meropenem ISF penetration was estimated at 63% (60%-69%) and 69% (65%-74%) for Profiles A and B, respectively, using comparative plasma and ISF AUCs. For Profile A, the plasma elimination t1/2 was 3.7 (3.3-4.0) h, the volume of distribution was 0.35 (0.25-0.46) L/kg, the total clearance was 4.1 (4.1-4.8) L/h and the CVVHDF clearance was 2.9 (2.7-3.1) L/h.\",\n",
    "    \"choices\": [\n",
    "      \"Yes\",\n",
    "      \"No\",\n",
    "      \"Maybe\"\n",
    "    ],\n",
    "\n",
    "    \"explanation\": \"This is the first known report of concurrent plasma and ISF concentrations of a meropenem antibiotic during CVVHDF. We observed that the ISF concentrations of meropenem were significantly lower than the plasma concentrations, although the present dose was appropriate for infections caused by intermediately susceptible pathogens (MIC<=4 mg/L).\",\n",
    "    \"answer\": \"B\",\n",
    "    \"answer_text\": \"No\"\n",
    "  },\n",
    "  {\n",
    "    \"question\": \"Does a family meetings intervention prevent depression and anxiety in family caregivers of dementia patients?\",\n",
    "    \"context\" : \"Family caregivers of dementia patients are at increased risk of developing depression or anxiety. A multi-component program designed to mobilize support of family networks demonstrated effectiveness in decreasing depressive symptoms in caregivers. However, the impact of an intervention consisting solely of family meetings on depression and anxiety has not yet been evaluated. This study examines the preventive effects of family meetings for primary caregivers of community-dwelling dementia patients. A randomized multicenter trial was conducted among 192 primary caregivers of community dwelling dementia patients. Caregivers did not meet the diagnostic criteria for depressive or anxiety disorder at baseline. Participants were randomized to the family meetings intervention (n=96) or usual care (n=96) condition. The intervention consisted of two individual sessions and four family meetings which occurred once every 2 to 3 months for a year. Outcome measures after 12 months were the incidence of a clinical depressive or anxiety disorder and change in depressive and anxiety symptoms (primary outcomes), caregiver burden and quality of life (secondary outcomes). Intention-to-treat as well as per protocol analyses were performed. A substantial number of caregivers (72/192) developed a depressive or anxiety disorder within 12 months. The intervention was not superior to usual care either in reducing the risk of disorder onset (adjusted IRR 0.98; 95% CI 0.69 to 1.38) or in reducing depressive (randomization-by-time interaction coefficient=-1.40; 95% CI -3.91 to 1.10) or anxiety symptoms (randomization-by-time interaction coefficient=-0.55; 95% CI -1.59 to 0.49). The intervention did not reduce caregiver burden or their health related quality of life.\",\n",
    "    \"choices\": [\n",
    "      \"Yes\",\n",
    "      \"No\",\n",
    "      \"Maybe\"\n",
    "    ],\n",
    "\n",
    "     \"explanation\": \"This study did not demonstrate preventive effects of family meetings on the mental health of family caregivers. Further research should determine whether this intervention might be more beneficial if provided in a more concentrated dose, when applied for therapeutic purposes or targeted towards subgroups of caregivers.\",\n",
    "    \"answer\": \"B\",\n",
    "    \"answer_text\": \"No\"\n",
    "  },\n",
    "  {\n",
    "    \"question\": \"Do follow-up recommendations for abnormal Papanicolaou smears influence patient adherence?\",\n",
    "    \"context\" : \"To compare adherence to follow-up recommendations for colposcopy or repeated Papanicolaou (Pap) smears for women with previously abnormal Pap smear results. Retrospective cohort study. Three northern California family planning clinics. All women with abnormal Pap smear results referred for initial colposcopy and a random sample of those referred for repeated Pap smear. Medical records were located and reviewed for 90 of 107 women referred for colposcopy and 153 of 225 women referred for repeated Pap smears. Routine clinic protocols for follow-up–telephone call, letter, or certified letter–were applied without regard to the type of abnormality seen on a Pap smear or recommended examination. Documented adherence to follow-up within 8 months of an abnormal result. Attempts to contact the patients for follow-up, adherence to follow-up recommendations, and patient characteristics were abstracted from medical records. The probability of adherence to follow-up vs the number of follow-up attempts was modeled with survival analysis. Cox proportional hazards models were used to examine multivariate relationships related to adherence. The rate of overall adherence to follow-up recommendations was 56.0% (136/243). Adherence to a second colposcopy was not significantly different from that to a repeated Pap smear (odds ratio, 1.40; 95% confidence interval, 0.80-2.46). The use of as many as 3 patient reminders substantially improved adherence to follow-up. Women without insurance and women attending 1 of the 3 clinics were less likely to adhere to any follow-up recommendation (hazard ratio for no insurance, 0.43 [95% confidence interval, 0.20-0.93], and for clinic, 0.35 [95% confidence interval, 0.15-0.73]).\",\n",
    "    \"choices\": [\n",
    "      \"Yes\",\n",
    "      \"No\",\n",
    "      \"Maybe\"\n",
    "    ],\n",
    "\n",
    "    \"explanation\": \"Adherence to follow-up was low in this family planning clinic population, no matter what type of follow-up was advised. Adherence was improved by the use of up to 3 reminders. Allocating resources to effective methods for improving adherence to follow-up of abnormal results may be more important than which follow-up procedure is recommended.\",\n",
    "    \"answer\": \"B\",\n",
    "    \"answer_text\": \"No\"\n",
    "  }\n",
    "]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 69,
   "id": "40d372d5-6218-4d10-953e-951f8e1bde43",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The following are multiple choice questions about medical research. Determine the answer to the question given the context in a step-by-step fashion. Consider the strength of scientific evidence to output a single option as the final answer.\n",
      "\n",
      "Context: To describe the interstitial fluid (ISF) and plasma pharmacokinetics of meropenem in patients on continuous venovenous haemodiafiltration (CVVHDF). This was a prospective observational pharmacokinetic study. Meropenem (500 mg) was administered every 8 h. CVVHDF was targeted as a 2-3 L/h exchange using a polyacrylonitrile filter with a surface area of 1.05 m2 and a blood flow rate of 200 mL/min. Serial blood (pre- and post-filter), filtrate/dialysate and ISF concentrations were measured on 2 days of treatment (Profiles A and B). Subcutaneous tissue ISF concentrations were determined using microdialysis. A total of 384 samples were collected. During Profile A, the comparative median (IQR) ISF and plasma peak concentrations were 13.6 (12.0-16.8) and 40.7 (36.6-45.6) mg/L and the trough concentrations were 2.6 (2.4-3.4) and 4.9 (3.5-5.0) mg/L, respectively. During Profile B, the ISF trough concentrations increased by ∼40%. Meropenem ISF penetration was estimated at 63% (60%-69%) and 69% (65%-74%) for Profiles A and B, respectively, using comparative plasma and ISF AUCs. For Profile A, the plasma elimination t1/2 was 3.7 (3.3-4.0) h, the volume of distribution was 0.35 (0.25-0.46) L/kg, the total clearance was 4.1 (4.1-4.8) L/h and the CVVHDF clearance was 2.9 (2.7-3.1) L/h.\n",
      "Question: Are interstitial fluid concentrations of meropenem equivalent to plasma concentrations in critically ill patients receiving continuous renal replacement therapy?\n",
      "Choices: \n",
      "A. Yes \n",
      "B. No \n",
      "C. Maybe\n",
      "Explanation: This is the first known report of concurrent plasma and ISF concentrations of a meropenem antibiotic during CVVHDF. We observed that the ISF concentrations of meropenem were significantly lower than the plasma concentrations, although the present dose was appropriate for infections caused by intermediately susceptible pathogens (MIC<=4 mg/L).\n",
      "Answer: B\n",
      "\n",
      "Context: Family caregivers of dementia patients are at increased risk of developing depression or anxiety. A multi-component program designed to mobilize support of family networks demonstrated effectiveness in decreasing depressive symptoms in caregivers. However, the impact of an intervention consisting solely of family meetings on depression and anxiety has not yet been evaluated. This study examines the preventive effects of family meetings for primary caregivers of community-dwelling dementia patients. A randomized multicenter trial was conducted among 192 primary caregivers of community dwelling dementia patients. Caregivers did not meet the diagnostic criteria for depressive or anxiety disorder at baseline. Participants were randomized to the family meetings intervention (n=96) or usual care (n=96) condition. The intervention consisted of two individual sessions and four family meetings which occurred once every 2 to 3 months for a year. Outcome measures after 12 months were the incidence of a clinical depressive or anxiety disorder and change in depressive and anxiety symptoms (primary outcomes), caregiver burden and quality of life (secondary outcomes). Intention-to-treat as well as per protocol analyses were performed. A substantial number of caregivers (72/192) developed a depressive or anxiety disorder within 12 months. The intervention was not superior to usual care either in reducing the risk of disorder onset (adjusted IRR 0.98; 95% CI 0.69 to 1.38) or in reducing depressive (randomization-by-time interaction coefficient=-1.40; 95% CI -3.91 to 1.10) or anxiety symptoms (randomization-by-time interaction coefficient=-0.55; 95% CI -1.59 to 0.49). The intervention did not reduce caregiver burden or their health related quality of life.\n",
      "Question: Does a family meetings intervention prevent depression and anxiety in family caregivers of dementia patients?\n",
      "Choices: \n",
      "A. Yes \n",
      "B. No \n",
      "C. Maybe\n",
      "Explanation: This study did not demonstrate preventive effects of family meetings on the mental health of family caregivers. Further research should determine whether this intervention might be more beneficial if provided in a more concentrated dose, when applied for therapeutic purposes or targeted towards subgroups of caregivers.\n",
      "Answer: B\n",
      "\n",
      "Context: To compare adherence to follow-up recommendations for colposcopy or repeated Papanicolaou (Pap) smears for women with previously abnormal Pap smear results. Retrospective cohort study. Three northern California family planning clinics. All women with abnormal Pap smear results referred for initial colposcopy and a random sample of those referred for repeated Pap smear. Medical records were located and reviewed for 90 of 107 women referred for colposcopy and 153 of 225 women referred for repeated Pap smears. Routine clinic protocols for follow-up–telephone call, letter, or certified letter–were applied without regard to the type of abnormality seen on a Pap smear or recommended examination. Documented adherence to follow-up within 8 months of an abnormal result. Attempts to contact the patients for follow-up, adherence to follow-up recommendations, and patient characteristics were abstracted from medical records. The probability of adherence to follow-up vs the number of follow-up attempts was modeled with survival analysis. Cox proportional hazards models were used to examine multivariate relationships related to adherence. The rate of overall adherence to follow-up recommendations was 56.0% (136/243). Adherence to a second colposcopy was not significantly different from that to a repeated Pap smear (odds ratio, 1.40; 95% confidence interval, 0.80-2.46). The use of as many as 3 patient reminders substantially improved adherence to follow-up. Women without insurance and women attending 1 of the 3 clinics were less likely to adhere to any follow-up recommendation (hazard ratio for no insurance, 0.43 [95% confidence interval, 0.20-0.93], and for clinic, 0.35 [95% confidence interval, 0.15-0.73]).\n",
      "Question: Do follow-up recommendations for abnormal Papanicolaou smears influence patient adherence?\n",
      "Choices: \n",
      "A. Yes \n",
      "B. No \n",
      "C. Maybe\n",
      "Explanation: Adherence to follow-up was low in this family planning clinic population, no matter what type of follow-up was advised. Adherence was improved by the use of up to 3 reminders. Allocating resources to effective methods for improving adherence to follow-up of abnormal results may be more important than which follow-up procedure is recommended.\n",
      "Answer: B\n",
      "\n",
      "\n",
      "Question: Are interstitial fluid concentrations of meropenem equivalent to plasma concentrations in critically ill patients receiving continuous renal replacement therapy?\n",
      "Choices:\n",
      "A. Yes\n",
      "B. No\n",
      "C. Maybe\n",
      "Explanation: \n",
      "Answer: \n"
     ]
    }
   ],
   "source": [
    "asm = tl[\"template\"].render(\n",
    "            context = sample['context'],\n",
    "            question=sample[\"question\"],\n",
    "            choices=sample[\"choices\"],\n",
    "    examples = examples\n",
    "        )\n",
    "\n",
    "print(asm)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "8308c8cc-eb19-447d-a51a-7d797fed5a5a",
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "from glob import glob\n",
    "from typing import List\n",
    "from jinja2 import Template, Environment, FileSystemLoader, meta, BaseLoader\n",
    "\n",
    "class TemplateLoader:\n",
    "    \"\"\"\n",
    "    A class for loading and managing Jinja2 templates. It allows loading templates from files or strings,\n",
    "    listing available templates, and getting template variables.\n",
    "    \"\"\"\n",
    "\n",
    "    def __init__(self):\n",
    "        \"\"\"\n",
    "        Initialize the TemplateLoader object and create an empty dictionary for loaded templates.\n",
    "        \"\"\"\n",
    "        self.loaded_templates = {}\n",
    "\n",
    "    def to_letter(self, index):\n",
    "        return chr(65 + index)\n",
    "\n",
    "    def load_template(\n",
    "        self, template: str, from_string: bool = False\n",
    "    ):\n",
    "        \"\"\"\n",
    "        Load a Jinja2 template either from a string or a file.\n",
    "\n",
    "        Args:\n",
    "            template (str): Template string or path to the template file.\n",
    "            from_string (bool): Whether to load the template from a string. Defaults to False.\n",
    "\n",
    "        Returns:\n",
    "            dict: Loaded template data.\n",
    "        \"\"\"\n",
    "        if template in self.loaded_templates:\n",
    "            return self.loaded_templates[template]\n",
    "\n",
    "        if from_string:\n",
    "            template_instance = Environment(loader=BaseLoader())\n",
    "            template_instance.filters['to_letter'] = self.to_letter\n",
    "            template = template_instance.from_string(template)\n",
    "            \n",
    "            template_data = {\n",
    "                \"template_name\": \"from_string\",\n",
    "                \"template_dir\": None,\n",
    "                \"environment\": template_instance,\n",
    "                \"template\":    template,\n",
    "            }\n",
    "            \n",
    "        else:\n",
    "            template_data = self._load_template_from_path(template)\n",
    "        self.loaded_templates[template] = template_data\n",
    "        return self.loaded_templates[template]\n",
    "\n",
    "    def _load_template_from_path(self, template: str) -> dict:\n",
    "        \"\"\"\n",
    "        Load a Jinja2 template from the given path.\n",
    "\n",
    "        Args:\n",
    "            template (str): Path to the template file.\n",
    "\n",
    "        Returns:\n",
    "            dict: Loaded template data.\n",
    "        \"\"\"\n",
    "        \n",
    "        self._verify_template_path(template)\n",
    "        custom_template_dir, custom_template_name = os.path.split(template)\n",
    "        environment = Environment(loader=FileSystemLoader(custom_template_dir))\n",
    "        environment.filters['to_letter'] = self.to_letter\n",
    "        template_instance = environment.get_template(custom_template_name)\n",
    "\n",
    "        return {\n",
    "            \"template_name\": custom_template_name,\n",
    "            \"template_dir\":  custom_template_dir,\n",
    "            \"environment\":   environment,\n",
    "            \"template\":      template_instance}\n",
    "\n",
    "    def _verify_template_path(self, templates_path: str):\n",
    "        \"\"\"\n",
    "        Verify the existence of the template file.\n",
    "\n",
    "        Args:\n",
    "            templates_path (str): Path to the template file.\n",
    "\n",
    "        Raises:\n",
    "            ValueError: If the template file does not exist.\n",
    "        \"\"\"\n",
    "        if not os.path.isfile(templates_path):\n",
    "            raise ValueError(f\"Templates path {templates_path} does not exist\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "758b8b71-91f8-4714-8183-3701bef2b8a4",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
